BioWorld MedTech

Oct. 21, 2011

Abbott reports plan to split into two separate companies

Two companies are better than one or so Abbott (Abbott Park, Illinois) has decided. The company plans to split into two publicly traded companies, one in diversified medical products and the other in research-based pharmaceuticals. Read More

Crimson's research memo details total cost of device documentation

International report: Cook's Spectrum Turbo-Ject PICC available in Canada

Washington roundup: FDA urged to tread lightly on artificial pancreas guidance

Agreements/contracts: Zimmer to distribute Benvenue's Kiva VCF

Deals roundup: Misonix sheds lab, forensic business for $1.5 million

Financings roundup: Sphere Medical looking to raise $24 million in an IPO

HIT roundup: Segasist wins first FDA 510(k) for Segasist P-AC

People in the News

Med-Tech Notes: RF Surgical works with UNC hospitals

Product Briefs

CareFusion initiates Class I recall of EnVe ventilators

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for May 20, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...